Loading...
Loading...
XCUR| Name | Value |
|---|---|
| Revenues | 21.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 21.8M |
| Operating Expense | 3.2M |
| Operating I/L | 18.6M |
| Other Income/Expense | 0.0M |
| Interest Income | 0.0M |
| Pretax | 18.6M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | 18.4M |
Exicure, Inc. is a biotechnology company specializing in developing therapies for neurological disorders and hair loss using its proprietary spherical nucleic acid (SNA) technology. The company's lead program candidate, SCN9A, is undergoing preclinical studies for neuropathic and chronic pain. Exicure has collaboration agreements with AbbVie Inc. to develop SNA-based treatments for hair loss disorders and with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
